SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Apple Turns 50: From Garage Startup to AI Crossroads 
TUCSON, Ariz., Sept. 06, 2017 -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, today announced its management will present at the Rodman and Renshaw 19th Annual Global Investment Conference in New York City on Monday, September 11, 2017, at 5:00 p.m. Eastern Time.
A live audio webcast of the presentation can be accessed by visiting the “Investors” section of the Company’s website at: http://www.htgmolecular.com. The webcast will be available on HTG's website for 90 days following the completion of the presentation.
About HTG:
Headquartered in Tucson, Arizona, the mission of HTG Molecular Diagnostics (HTG) is to empower precision medicine at the local level. The company’s HTG EdgeSeq technology, which automates sample and targeted library preparation for next-generation sequencing, received its first US Patent in 2014. Continuous improvements led to the 2017 launch of its new direct-target sequencing chemistry for DNA analysis. Additional information is available at www.htgmolecular.com.
CONTACT: Ashley Robinson LifeSci Advisors, LLC 617-775-5956 [email protected] TJ Johnson President/CEO HTG Molecular Diagnostics 520-547-2827 x130 [email protected]
